

Clinical Pharmacy Program Guidelines for Oxervate

Program	Prior Authorization
Medication	Oxervate (cenegermin-bkbj) ophthalmic solution
Markets in Scope	Arizona, California, Colorado, Hawaii, Maryland, Nevada, New Jersey, New York CHIP, New York EPP, Pennsylvania-CHIP, Rhode Island, South Carolina
Issue Date	2/2019
Pharmacy and Therapeutics Approval Date	2/2021
Effective Date	4/2021

1. Background:

Oxervate (cenegermin-bkbj) ophthalmic solution is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis.

2. Coverage Criteria:

<p>A. <u>Authorization</u></p> <p>1. Oxervate will be approved based on <u>all</u> the following criteria:</p> <p style="padding-left: 40px;">a. Diagnosis of Stage 2 or 3 neurotrophic keratitis</p> <p style="text-align: center;">-AND-</p> <p style="padding-left: 40px;">b. History of failure to at least <u>one</u> OTC ocular artificial tear product (e.g., Systane® Ultra, Akwa® Tears, Refresh Optive®, Soothe® XP)</p> <p style="text-align: center;">-AND-</p> <p style="padding-left: 40px;">c. Prescribed by or in consultation with <u>one</u> of the following:</p> <p style="padding-left: 80px;">(a) Ophthalmologist</p> <p style="padding-left: 80px;">(b) Optometrist</p> <p style="text-align: center;">Authorization will be issued for one 8 week authorization.</p>
--

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Oxervate [package insert]. Boston, MA: Dompé U.S. Inc.; October 2019.
2. Sacchetti, M., Lambiase, A. Diagnosis and management of neurotrophic keratitis. *Clinical Ophthalmology* 2014;8: 571-9.

Program	Prior Authorization
Change Control	
Date	Change
2/2019	New program
2/2020	Annual review. Updated references.
2/2021	Annual review. No changes.